Expert Viewpoints
Expert Viewpoint January 2009
Hugo R. Rosen, MD, discusses recent advances in the treatment of hepatocellular carcinoma including local ablative therapies and liver transplantation.
Nyingi M. Kemmer, MD, MPH; and Guy Neff, MD, MBA, discuss new data from AASLD on new therapies with improved efficacy, safety, and tolerability for hepatic encephalopathy.
Emmet B. Keeffe, MD, explains a newly developed “road map” that provides guidance for optimizing treatment of patients with chronic hepatitis B.
David L. Thomas, MD, MPH, discusses the controversial topic of whether SVR means cure in the treatment of hepatitis C and reviews evidence from a recent study by Swain and coworkers that supports using these terms interchangeably.
Patrick Marcellin, MD, provides regional perspectives from France on screening hepatitis C patients for depressive symptoms and strategies for preventing depression development during HCV therapy.
Martin Schaefer, MD, discusses how treatment approaches for the treatment of interferon-induced psychiatric symptoms differ between the US and Europe.
Karen L. Lindsay, MD, discusses aims and scope of the Ribavirin Pregnancy Registry for evaluating outcomes of pregnancies exposed to ribavirin either by direct maternal exposure or by indirect paternal exposure.
Robert G. Gish, MD, reviews the latest data on diagnosis and treatment, including drugs in development.
Dr. Veenstra explores the challenges of cost-effectiveness analysis for treatment of chronic hepatitis B.
Adrian M. Di Bisceglie, MD, FACP, argues that successful therapy for HBV will halt progression and, given sufficient time, may allow the liver to heal itself.
The most important factor driving the increase in HBV prevalence in the US and Western Europe is immigration from higher prevalence regions of the world.
Drs. Keeffe and Crocket review the little studied area of HBV/HCV coinfection and provide a framework for treatment.
What is the prognosis for liver biopsy? Dr. Nezam Afdhal weighs the pros and cons of the noninvasive tests.
A disease which had previously been considered rare must now be included in the differential diagnosis of all patients with acute or chronic liver disease or allograft dysfunction after liver transplantation., Dr. Czaja states.
Dr. Locarnini provides both a clear analysis of what leads to resistance as well as a practical approach to its avoidance.
Dr. Jorge Marrero looks at the challenges of conducting a successful HCC screening program.
Dr. Scott L. Nyberg discusses the potential uses of the bioartificial liver in treating acute and chronic liver failure.
Kris V. Kowdley, MD, discusses the impact of HBV in the Asia-Pacific region, based on a special presentation from the APASL conference.
HCV is likely the most prevalent bloodborne infection in US prisons.
Kathleen B. Schwarz, MD, discusses the possible roads for managing the HCV-infected child
We know know how to prevent most perinatal transmission of hepatitis B.
Is an HCV vaccine possible? Dr. David L. Thomas, MD, MPH, rates the odds.
Adrian M. Di Bisceglie, MD, FACP, examines whether we should be using growth factors for HCV patients.
|